VALSTAR® (valrubicin) is indicated for intravesical therapy of BCG-refractory carcinoma in situ (CIS) of the urinary bladder in patients for whom immediate cystectomy would be associated with unacceptable morbidity or mortality.
VALSTAR® (valrubicin) is indicated for intravesical therapy of BCG-refractory carcinoma in situ (CIS) of the urinary bladder in patients for whom immediate cystectomy would be associated with unacceptable morbidity or mortality.
Please see full Prescribing Information.
VALSTAR® (valrubicin) is indicated for intravesical therapy of BCG-refractory carcinoma in situ (CIS) of the urinary bladder in patients for whom immediate cystectomy would be associated with unacceptable morbidity or mortality.
Please see full Prescribing Information.
Please try again on your desktop, laptop, or 9" or larger tablet browser.
You can also view the full site.